Nada Božina (Nada Bozina)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 13

Top Topics

Replacement Therapy

Clinical Decision Support

Prognostic Factors

Top Venues

Pharmacogenomics

European journal of clinical pharmacology

Journal of clinical pharmacy and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics (2023)
Nada Božina, Ivana Šušak Sporiš, Iva Klarica Domjanović, Lana Ganoci, Livija Šimičević, Mila Lovrić, Zrinka Čolak Romić, Željka Petelin Gadže, Vladimir Trkulja
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy. European journal of clinical pharmacology (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Lucija Lešnjaković, Lana Ganoci, Ivan Bilić, Livija Šimičević, Iva Mucalo, Stjepko Pleština, Nada Božina
DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics 24 (2) (2023)
Gordana Nedic Erjavec, Mirko Grubor, Maja Zivkovic, Nada Božina, Marina Šagud, Matea Nikolac Perkovic, Alma Mihaljevic-Peles, Nela Pivac, Dubravka Švob Štrac
SLC6A3 , HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism. Biomedicines 10 (12) (2022)
Livija Šimičević, Iva Canjuga, Lada Zibar, Ana Borić-Bilušić, Lana Ganoci, Nada Božina
Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes. Journal of clinical pharmacy and therapeutics 47 (9) (2022)
Gordana Nedic Erjavec, Mirko Grubor, Maja Zivkovic, Nada Božina, Marina Šagud, Matea Nikolac Perkovic, Alma Mihaljevic-Peles, Nela Pivac, Dubravka Švob Štrac
SLC6A3 , HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism. Biomedicines 10 (12) (2022)
Iveta Merćep, Ivana Radman, Vladimir Trkulja, Tamara Božina, Livija Šimičević, Ema Budimir, Lana Ganoci, Nada Božina
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. European journal of clinical pharmacology (2021)
Darija Kuruc Poje, Nada Božina, Livija Šimičević, Igor Žabić
Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report. Journal of clinical pharmacy and therapeutics 45 (4) (2020)
Iva Klarica Domjanović, Mila Lovrić, Vladimir Trkulja, Željka Petelin-Gadže, Lana Ganoci, Ivana Čajić, Nada Božina
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. British journal of clinical pharmacology 84 (9) (2018)